First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: Results of a one-year study

Terapevticheskii Arkhiv

Volumn 85, Issue 3, 2013, Pages 38-43

  Avdeev, S N ^a   Tsareva, N A ^a   Neklyudova, G V ^a   Chuchalin, A G ^a  

^a FEDERAL BIOMEDICAL AGENCY OF RUSSIA   (Russian Federation)

Author keywords

Bosentan; Endothelin receptor antagonists; Pulmonary hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; BOSENTAN; ENDOTHELIN RECEPTOR; SULFONAMIDE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ENDOTHELIN; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879428701     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Galiè N., Hoeper M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2009;30:2493-2537.
2. Galie N., Hoeper M. M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-1263.
3. McLaughlin V. V., Archer S. L., Badesch D. B. et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-2294.
4. Badesch B. D., Champion H. C., Gomez-Sanchez MA. et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S55-S56.
5. Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-1030.
6. Peacock A. J., Murphy N. F., McMurray JJ. V. et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30:104-109.
7. Humbert M., Sitbon O., Slmonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
8. Sitbon O., Humbert M., Jais X. et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3 111.
9. Galie N., Manes A., Branzi A. The endothelin system in pulmonary hypertension. Cardiovasc Res 2004;61:227-237.
10. Rubens C., Ewert R., Halank M. et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120:1562-1569.
11. Bauer M., Wilkens H. C., Langer F. et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002;105:1034-1036.
12. Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med 2007;28:117-125.
13. Dupuis J., Hoeper M. M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;31:407-415.
14. Channick R. N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-1123.
15. Rubin L. J., Badesch D. B., Barst R. J. et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
16. Galiè N., Rubin L. J., Hoeper M. M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-2100.
17. ATS. ATS statement: guidelines for the 6-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
18. Berger M., Haimowitz A., Van Tosh A. et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985;6:359-365.
19. Kitabatake A., Inoue M., Asao M. et al. Noninvasive evaluation of pulmonary hypertension by a pulsed doppler technique. Circulation 1983;68:302-309.
20. Sitbon O., Badesch D. B., Channick R. N. Effects of the dual endothelin-1 receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-254.
21. McLaughlin V. V., Sitbon O., Badesch D. B. et al. Survival with firstline bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-249.
22. D'Alonzo G. E., Bant R. J., Ayres S. M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.
23. Provencher S., Sitbon O., Humbert M. et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006;27:589-595.
24. Roman A., Gispert P., Monfort V. et al. Long-term outcomes of treatment with bosentan in pulmonary hypertension. Arch Bronconeumol 2006;42:616-620.